Global Urothelial Cancer Drugs Market Trends, Growth Rate and Forecasts 2025
6-nov-2018 This report focuses on the global Urothelial Cancer Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Urothelial Cancer Drugs development in United States, Europe and China. Urothelial carcinoma or transitional cell carcinoma is a malignant neoplasm occurring from urothelium. The disease is the ninth most common malignancy in the world, with approximately 2.5 million patients and 420,000 newly diagnosed cases each year. Bladder transitional cell carcinoma (TCC) accounted for approximately 90% of all urinary cancer cases. Market growth is largely attributed to factors such as availability of novel drugs, presence of a strong pipeline, rise in incidence of urothelial cancer due to growing geriatric population, unorganized lifestyle, and rising public awareness. In 2017, the global Urothelial Cancer Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with...